Organon’s XACIATO (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older - Seite 2

“BV is the most common form of vaginitis,^1,9 disrupting the lives of approximately 21 million women.^1,5 For these women, it’s important to consider her individual treatment needs, such as route of administration, cost, adverse events, dosing and duration of treatment,”^7,10 said Erica Montes, M.D., Board-Certified Obstetrician and Gynecologist and a Fellow of the American College of OB/GYN. “The availability of XACIATO is important as it’s one dose for women experiencing BV and it can be taken at any time of day.”

In 2022, Organon and Daré Biosciences completed an agreement whereby Organon will license global rights to XACIATO.

Information about XACIATO, and the eVoucher instant savings coupon for eligible patients, can be found at XACIATO.com.

About BV

BV is the most common vaginal condition in women of reproductive age in the United States, affecting approximately 21 million women.^1,5 The condition results from an overgrowth of certain bacteria, which upsets the balance of the natural vaginal microbiome and can lead to symptoms of odor or discharge.³ BV may self-resolve in up to 30% of women, but most symptomatic women require treatment.^6,11 If left untreated, BV may lead to serious complications.^2,11 BV has also been shown to disproportionately affect non-Hispanic Black and Mexican American women.^4,5

About XACIATO

XACIATO is indicated for the treatment of bacterial vaginosis in females 12 years and older. A single-dose user-filled disposable applicator delivers 5g of vaginal gel containing 100mg of clindamycin.

Selected Safety Information

XACIATO is contraindicated in individuals with a history of hypersensitivity to clindamycin or lincomycin.

Clostridioides difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including clindamycin, and may range in severity from mild diarrhea to fatal colitis. Careful medical history is necessary since CDAD has been reported to occur over 2 months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial use not directed against C. difficile may need to be discontinued.

Polyurethane condoms are not recommended during treatment with XACIATO or for 7 days following treatment. During this time period, polyurethane condoms may not be reliable for preventing pregnancy or for protecting against transmission of HIV and other sexually transmitted diseases. Latex or polyisoprene condoms should be used.